Semaglutide (GLP-1)
Medical Weight Loss
Is Semaglutide (GLP-1) Right for You?
Patients who consult with us about Semaglutide (GLP-1) often have:
- •BMI ≥27 with weight-related health concerns, or BMI ≥30
- •Seeking physician-supervised weight management support
- •Struggled with traditional diet and exercise approaches
- •Committed to lifestyle modifications alongside medication
- •Metabolic health concerns such as insulin resistance or pre-diabetes
- •Desire a comprehensive, medically-guided approach to weight management
Consultation Required: Semaglutide requires a comprehensive medical evaluation, lab work, and ongoing monitoring by Dr. Vaidya. Not all patients are suitable candidates.
Contraindications: Contraindications include: Personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, pregnancy/nursing, type 1 diabetes, severe gastrointestinal disease, and other conditions as determined by your physician.
About Semaglutide (GLP-1)
Semaglutide is an FDA-approved GLP-1 (glucagon-like peptide-1) receptor agonist. While it has FDA approval for type 2 diabetes management and chronic weight management (as Wegovy®), we prescribe compounded semaglutide, which is not FDA-approved.
Mechanism of Action (Based on Research)
Preclinical studies suggest Semaglutide (GLP-1) may influence:
- •Regulates appetite signals in the brain
- •Slows gastric emptying, promoting satiety
- •Supports blood glucose regulation
- •Influences metabolic pathways
Important: FDA-approved semaglutide (Wegovy®) clinical trials showed participants lost an average of 12.4% of initial body weight over 68 weeks. Results were achieved in combination with reduced-calorie diet and increased physical activity. Individual results varied widely; not all participants achieved significant weight loss. These results are from FDA-approved formulations studied in clinical trials. Compounded semaglutide may differ in efficacy, safety, and outcomes.
Your Semaglutide Program
Important Safety Information
Common side effects may include:
- •Nausea, vomiting, diarrhea (usually mild and temporary)
- •Constipation, abdominal discomfort
- •Fatigue, headache
- •Injection site reactions
Serious risks include:
- •Thyroid C-cell tumors (see black box warning)
- •Pancreatitis
- •Gallbladder problems
- •Kidney problems
- •Diabetic retinopathy complications
- •Allergic reactions
You must discuss all risks and benefits with Dr. Vaidya before starting treatment.
Weight Management Approach Comparison
| Approach | Evidence | Supervision | Sustainability |
|---|---|---|---|
| Physician-Supervised GLP-1 Therapy | Strong for FDA-approved versions | Required | Requires ongoing lifestyle changes |
| Diet & Exercise | Strong foundation | Variable | Long-term commitment essential |
| Commercial Programs | Variable | Typically coaching | Depends on individual |
| Bariatric Surgery | Strong for severe obesity | Surgical team | Lifelong dietary changes required |
Note: No approach guarantees weight loss. Success depends on individual adherence, metabolism, medical history, and numerous other factors.
Patient Experiences
Individual testimonials do not represent typical results. Weight loss results vary significantly based on starting weight, adherence, metabolism, medical history, and other individual factors. These patients also implemented diet and lifestyle changes.
“With Dr. Vaidya's guidance, I lost weight over 6 months using semaglutide combined with dietary changes. My experience was positive, though I know everyone's journey is different. The medical supervision was invaluable.”
— S.M., Cary, NC
Results not typical. Patient also followed reduced-calorie diet and exercise program.
“I worked with Dr. Vaidya on a comprehensive plan that included semaglutide. Over several months, my weight decreased and my metabolic markers improved. I'm grateful for the support throughout the process.”
— R.P., Raleigh, NC
Results not typical. Patient had pre-diabetes at baseline and followed medical nutrition therapy.
“After years of struggling, I finally found an approach that worked for me with Dr. Vaidya's medical weight management program. The medication helped reduce my appetite while I learned sustainable eating habits.”
— K.T., Durham, NC
Results not typical. Individual outcomes vary.
Disclaimer: These testimonials represent individual experiences only and are not indicative of typical results. Weight loss outcomes vary significantly. Some patients may experience minimal or no weight loss. All patients followed comprehensive lifestyle modification programs in addition to medication. No guarantee of results can be made.
Frequently Asked Questions
How much weight can I lose with Semaglutide?▼
Clinical studies showed average weight loss of 12.4% of body weight over 68 weeks when combined with diet and exercise. Individual results vary significantly.
What are the side effects?▼
Common side effects may include nausea, which often diminishes over time. We start with low doses to help minimize discomfort. Dr. Vaidya will review all potential side effects including serious risks.
Is Semaglutide FDA approved?▼
Semaglutide is FDA-approved for chronic weight management under brand names Wegovy and Ozempic. However, we prescribe compounded semaglutide which is not FDA-approved.
Related Health Goals
Nearby Locations
Our clinic at 8020 Creedmoor Rd, Raleigh, NC 27613 serves patients throughout the Triangle area.
Board-Certified in Family Practice and Anti-Aging Medicine. Practicing since 2005. Dr. Vaidya leads both Regenesis MD and Peptide Therapy Raleigh, offering integrative medicine combining peptide therapy, stem cells, hormone optimization, and medical aesthetics under one roof.
Read full bio →Medical Disclaimer: Semaglutide (GLP-1) is administered under the direct supervision of Dr. Bhavna Vaidya, MD. Semaglutide (GLP-1) is FDA-approved for specific indications. However, clinic protocols may differ from FDA-labeled use. Individual results vary. Please schedule a consultation to discuss whether this therapy is appropriate for your health goals.
Treatment Details
Free 10-minute Peptide Discovery Call
FDA Status: Semaglutide (Wegovy®, Ozempic®) is FDA-approved for chronic weight management and type 2 diabetes. However, we prescribe compounded semaglutide, which is not FDA-approved. The FDA has not evaluated the safety or effectiveness of compounded semaglutide.
Not Medical Advice: The information on this page is for educational purposes only and does not constitute medical advice. Only Dr. Vaidya can determine if this treatment is appropriate for you after a comprehensive medical evaluation.
Individual Results Vary: Testimonials and patient experiences shared on this page represent individual outcomes and are not typical. Many patients may experience different results or no benefit. No guarantee of specific results can be made.
Important Medical & Legal Information
Informed Consent Required: All treatments require informed consent after discussion of risks, benefits, alternatives, and realistic expectations.
North Carolina Medical Board Compliance: This practice operates in full compliance with North Carolina Medical Board regulations. All advertising and patient communications are truthful, not misleading, and substantiated by available evidence.
Questions or Concerns: If you have questions about any treatment, potential risks, expected outcomes, or alternatives, please schedule a consultation with Dr. Vaidya at 919-322-2844.
Ready to Explore Semaglutide (GLP-1)?
Book a free 10-minute Peptide Discovery Call to discuss your health goals with our team.
Book Your Discovery CallOr call (919) 322-2844
